Evidence map›Paper›PMID 38873158›Full record

ArticleFrontiers in microbiology2024

Engineered probiotic cocktail with two cascade metabolic

Feng Geng, Mingyu Wu, Pan Yang, Xueling Li, Xiaohong Pan, Yadi Wang, Junhong Lü

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Feng Geng *College of Pharmacy, Binzhou Medical University, Yantai, China.
Mingyu Wu *College of Pharmacy, Binzhou Medical University, Yantai, China.
Pan YangCollege of Pharmacy, Binzhou Medical University, Yantai, China.
Xueling LiJinan Microecological Biomedicine Shandong Laboratory, Jinan, China.
Xiaohong PanCollege of Pharmacy, Binzhou Medical University, Yantai, China.
Yadi WangCollege of Pharmacy, Binzhou Medical University, Yantai, China.
Junhong LüCollege of Pharmacy, Binzhou Medical University, Yantai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Engineering probiotics have emerged as a potential strategy for the treatment of metabolic diseases. However, due to the exceptional complexity of these metabolic disorders and the intricate relationship between gut microbes, it is difficult to achieve an ideal therapeutic effect in a specific metabolic disorder using only a single engineered strain. In this work, we proposed a probiotic cocktail strategy by engineering two cascade metabolic bacteria to treat hyperlysinemia, an inherited lysine metabolic disorder with loss of α-aminoadipate semialdehyde synthase (AASS) activity. A probiotic

Indexed as

cocktailengineered probioticsEscherichia colihyperlysinemiametabolic diseases

Identifiers

PMID38873158
PMCPMC11169572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.